U. Scheuring
AstraZeneca
10 Papers
22 Citations
U. Scheuring is an academic researcher from AstraZeneca. The author has contributed to research in topics: Durvalumab & Tremelimumab. The author has an hindex of 7, co-authored 10 publications.
Chat about Author
Papers
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi,Byoung Chul Cho,Niels Reinmuth,Ki Hyeong Lee,Alexander Luft,Myung-Ju Ahn,Michel M. van den Heuvel,M. Cobo,David Vicente,Alexey Smolin,Vladimir Moiseyenko,Scott J. Antonia,Sylvestre Le Moulec,Gilles Robinet,Ronald B. Natale,Jeffrey Gary Schneider,Frances A. Shepherd,Sarayut Lucien Geater,Edward B. Garon,Edward S. Kim,Sarah B. Goldberg,Kazuhiko Nakagawa,Rajiv Raja,Brandon Higgs,Anne-Marie Boothman,Luping Zhao,U. Scheuring,Paul K. Stockman,Vikram Chand,Solange Peters,Mystic Investigators +30 more
TL;DR: Treatment with durvalumab resulted in a numerically reduced risk of death vs chemotherapy in patients with programmed cell death ligand 1 expression on at least 25% of tumor cells, highlighting the need for further investigation and prospective validation of blood tumor mutational burden as a predictive biomarker for immunotherapy.
558
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
David Planchard,Niels Reinmuth,Sergey Orlov,Juergen R. Fischer,S. Sugawara,S. Mandziuk,D. Marquez-Medina,Silvia Novello,Y. Takeda,Ross A. Soo,Kwang Bo Park,Michael McCleod,Sarayut Lucien Geater,M. Powell,R. May,U. Scheuring,Paul K. Stockman,Dariusz M. Kowalski +17 more
TL;DR: In heavily pretreated patients with mNSCLC, durvalumab demonstrated clinically meaningful improvements in OS and PFS versus SoC (patients with PD-L1 TC ≥25%); numerical improvements in overall survival and progression-free survival were observed.
140
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Han Si,M. Kuziora,Katie Quinn,Elena Helman,Jiabu Ye,F. Liu,U. Scheuring,Solange Peters,Naiyer A. Rizvi,Philip Z Brohawn,Koustubh Ranade,Brandon Higgs,Kimberly C. Banks,Vikram Chand,Rajiv Raja +14 more
TL;DR: In this article, the authors used the GuardantOMNI ctDNA platform for quantifying tumor mutational burden (TMB) in the blood of patients with non-small cell lung cancer.
Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.
Naiyer A. Rizvi,Byoung Chul Cho,Niels Reinmuth,Ki Hyeong Lee,Alexander Luft,Myung-Ju Ahn,Michel M. van den Heuvel,Manuel Cobo Dols,David Vicente,Alexey Smolin,Vladimir Moiseyenko,Scott J. Antonia,Kazuhiko Nakagawa,Sarah B. Goldberg,Edward S. Kim,Jill Walker,Rajiv Raja,F. Liu,U. Scheuring,Solange Peters +19 more
TL;DR: MySTIC, an open-label, Ph3 trial of first-line D (anti-PD-L1) ± T ( anti-CTLA-4) vs platinum-based CT, showed an improvement in OS with D vs CT in pts with tumor cell PD- L1 expressio...
16
Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study.
Niels Reinmuth,Byoung Chul Cho,K.H. Lee,Alexander Luft,Myung-Ju Ahn,Jeffrey Gary Schneider,Frances A. Shepherd,Sarayut Lucien Geater,Zsolt Papai-Szekely,T. Van Ngoc,M.C. Garassino,F. Liu,Delyth Clemett,P. Thiyagarajah,Mario Ouwens,U. Scheuring,Solange Peters,Naiyer A. Rizvi +17 more
11